Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022
Organogenesis Holdings Inc. (Nasdaq: ORGO) will announce its first quarter fiscal 2022 financial results after market close on May 10th.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Organogenesis Holdings Inc. (Nasdaq: ORGO) will announce its first quarter fiscal 2022 financial results after market close on May 10th. Following the announcement, management will host a conference call at 5:00 p.m. ET to discuss the results and provide a corporate update, including a Q&A session. Participants can join by dialing 866-795-3142 or 409-937-8908 for international calls, using access code 3349739. A live webcast will also be available on the company's investor relations website, with an archive accessible for one year.
Details
News Market Reaction – ORGO
The recorded move for ORGO in the trading session of this news was -1.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2022 financial results will be reported after the market closes on Tuesday, May 10th.
Management will host a conference call at 5:00 p.m. Eastern Time on May 10th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 3349739. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.
Investor Inquiries:
ICR Westwicke
Mike Piccinino, CFA
OrganoIR@westwicke.com
Press and Media Inquiries:
Organogenesis
Lori Freedman
lfreedman@organo.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.